Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 6/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14863707 | 0.85 | KDM4E (0.46) | MAOBMAOAHSD17B10ACHEFGFR1 | |
| SCHEMBL27978873 | 0.81 | CYP11B1 (0.47) | MAOBMAOAHSD17B10ACHEHTT | |
| SCHEMBL15185681 | 0.81 | HCAR3 (0.42) | HCAR3HSD17B10HTTPLA2G4AFGFR1 | |
| SCHEMBL27955207 | 0.79 | HCAR3 (0.41) | HCAR3MAOBMAOAHSD17B10ACHE | |
| SCHEMBL30159516 | 0.79 | MAOB (0.56) | HCAR3MAOBMAOAACHEHPGD | |
| SCHEMBL1144709 | 0.79 | MAOB (0.56) | HCAR3MAOBMAOAACHEHPGD | |
| SCHEMBL28180494 | 0.77 | CHEK1 (0.49) | HCAR3HSD17B10HTTPLA2G4AFGFR1 | |
| SCHEMBL8356173 | 0.77 | CHEK1 (0.65) | HCAR3MAOBHSD17B10HTTPLA2G4A | |
| SCHEMBL1667310 | 0.77 | PLA2G10 (0.55) | HPGD | |
| SCHEMBL31523364 | 0.76 | HCAR3 (0.42) | HCAR3MAOBHSD17B10HTTPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | HCAR3 4105/4885MAOB 1996/4885MAOA 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.